Improving predictions of adverse reactions to common pain medications using genetic data
Official title: Augmenting Pharmacogenetics with Multi-Omics Data and Techniques to Predict Adverse Drug Reactions to NSAIDs
Funded at University of Pennsylvania · NIH-10932146 · Data updated 2026-11-12
This study is looking at how your genes might affect your chances of having bad reactions to common pain relievers like ibuprofen, so that doctors can better predict who might be at risk and help everyone use these medications more safely.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 18, 2023 |
| Project end | October 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $48,974 |
| NIH project number | 5F31HG013246-02 |
| Project ID | NIH-10932146 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals who are prescribed NSAIDs and may be at risk for adverse drug reactions due to genetic factors.
✕Less likely to help
Patients who do not take NSAIDs or have no history of adverse drug reactions may not benefit from this research.
What this research studies
This research investigates how genetic factors influence the risk of adverse drug reactions (ADRs) from non-steroidal anti-inflammatory drugs (NSAIDs), which are commonly used for pain relief. By conducting a genome-wide association study in a diverse population, the researchers aim to identify genetic markers associated with ADRs. They will develop a polygenic risk score (PRS) and a transcriptomic risk score (TRS) to enhance the prediction of these risks. The study combines genetic data with clinical information to create a comprehensive model for predicting individual risk of ADRs, potentially leading to safer medication use.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of serious adverse drug reactions in patients taking NSAIDs.
How similar studies have gone: Previous research has shown promise in using genetic data to predict drug responses, indicating that this approach may lead to meaningful advancements in patient safety.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Keat, Karl Ernst — University of Pennsylvania
- Study coordinator: Keat, Karl Ernst
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.